Cytokinetics is dedicated to the discovery, development and commercialization of novel therapeutics within the emerging field of cytoskeletal pharmacology. The cytoskeleton is a complex, dynamic framework that impacts all aspects of cell function including division, motility, transport, muscle contractility and cellular organization. Cytokinetics' R&D efforts aim to address pharmaceutical needs in cancer, cardiovascular and infectious diseases and feature proprietary Cytometrix™ cellular phenotyping technologies designed to industrialize cell biology for increased speed and productivity in drug discovery and development. Cytokinetics and GlaxoSmithKline have begun Phase I studies with the first novel anti-cancer drug candidate under their collaboration. The company is building a promising pipeline of next-generation drug candidates arising from other internal pharmaceutical research programs and is planning the initiation of clinical studies for other potential first-in-class compounds.
Cytokinetics' mission is to translate the power of cell biology into novel pharmaceuticals and technologies with the objective to enhance patient care.
Rights and permissions
About this article
Cite this article
About Cytokinetics. Nature 422, 782 (2003). https://doi.org/10.1038/422782a
Issue Date:
DOI: https://doi.org/10.1038/422782a